IL6 and COVID-19: Whilst the exact dosing regimens vary between trials, COVID‐19 patients will be receiving a single or short‐course intravenous infusion or subcutaneous injection of the IL‐6 inhibitor (Clinical Trial Identifiers NCT04317092, NCT04315298, NCT04327388, NCT04330638, and NCT04322188).